Impact of China's drug policy will be visible soon, says Jefferies
The first tenders under the new drug program on China's insulin market are expected in late November and early December. The impact of said program is anticipated to be seen around the New Year, and implementation is slated for early 2022, according to the US-based bank Jefferies.
.jpg)
by marketwire, translated by daniel pedersen
China's new drug policy is predicted to have a big impact on Novo Nordisk's insulin sales on the lucrative national market, says the US-based bank Jefferies after a meeting with Novo's Daniel Bohsen, corporate vice president and head of investor relations at the company.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Raising ambitions at Novo Nordisk an obvious move, says CEO
For subscribers
.jpg)
.jpg&w=384&q=75)
